Physician profile
James E Martin
NPI 1144219502
$1,856.26
in general payments reported to CMS, 2019-2025
26 companies · $272 in 2025
The $272 reported for 2025 was more than what 82% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $432 · 2020: $221 · 2021: $162 · 2022: $255 · 2023: $150 · 2024: $365 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $560 · Travel and Lodging: $227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $560.04 |
| Travel and Lodging | $226.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $226.98 | 2024 | |
| Sanofi Pasteur INC. | $225.80 | 2019-2025 | |
| Ironshore Pharmaceuticals INC. | $201.07 | 2019-2024 | Jornay Pm |
| Pfizer INC. | $168.61 | 2020-2025 | |
| Tris Pharma INC | $152.36 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $121.12 | 2022 | |
| Corium, LLC | $115.18 | 2021-2022 | |
| Neos Therapeutics, Lp | $94.15 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $62.31 | 2019-2023 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Takeda Pharmaceuticals U.S.A., INC. | $55.66 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $51.65 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $48.58 | 2021-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $44.53 | 2020-2023 | Austedo Xr |
| Novartis Pharmaceuticals Corporation | $41.21 | 2019 | |
| Seqirus USA INC | $33.72 | 2021-2025 | Flucelvax |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $29.96 | 2023-2024 | Bexsero |
| Nestle Healthcare Nutrition INC. | $22.44 | 2023 | |
| Upsher-Smith Laboratories LLC | $22.30 | 2020 | |
| Ucb, INC. | $21.98 | 2022 | |
| Sobi, INC | $21.86 | 2020 | |
| Acadia Pharmaceuticals INC | $19.99 | 2023 | Daybue |
| Mdd US Operations, LLC | $16.97 | 2025 | Gocovri |
| Akcea Therapeutics, INC. | $15.11 | 2019 | |
| Genentech USA, INC. | $14.91 | 2019 | |
| Shire North American Group INC | $13.91 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $13.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.